Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Tg Therapeutics (TGTX) over the last 15 years, with Dec 2024 value amounting to $68,000.

  • Tg Therapeutics' Depreciation & Amortization (CF) rose 54.55% to $17,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $47,000, marking a year-over-year decrease of 51.55%. This contributed to the annual value of $68,000 for FY2024, which is 67.77% down from last year.
  • Per Tg Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $68,000 for FY2024, which was down 67.77% from $211,000 recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Depreciation & Amortization (CF) peaked at $303,000 during FY2022, and registered a low of $68,000 during FY2024.
  • For the 3-year period, Tg Therapeutics' Depreciation & Amortization (CF) averaged around $194,000, with its median value being $211,000 (2023).
  • In the last 5 years, Tg Therapeutics' Depreciation & Amortization (CF) surged by 78.48% in 2021 and then tumbled by 67.77% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Depreciation & Amortization (CF) stood at $158,000 in 2020, then surged by 78.48% to $282,000 in 2021, then increased by 7.45% to $303,000 in 2022, then crashed by 30.36% to $211,000 in 2023, then plummeted by 67.77% to $68,000 in 2024.